# Benchmark Electronics Inc: financial statements, quarterly

BHE · NYSE · CIK 863436 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bhe.md) · [Financials](/companies/bhe/financials.md) · [Filings](/companies/bhe/filings.md) · [Insiders](/companies/bhe/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/bhe/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q1 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [746](/filings/0000950170-24-119684.md) | [713 d](/filings/0001193125-26-064849.md) | [711](/filings/0000950170-25-061313.md) | [687](/filings/0000950170-25-100970.md) | [680](/filings/0001193125-25-266701.md) | [684 d](/filings/0001193125-26-064849.md) | [655](/filings/0001193125-26-192574.md) | [666](/filings/0001193125-26-324169.md) | [703](/filings/0001193125-25-266701.md) | [726 d](/filings/0001193125-26-064849.md) | [698](/filings/0001193125-26-192574.md) | [777](/filings/0001193125-26-324169.md) |
| Cost of revenue | $m | [651](/filings/0000950170-24-119684.md) | [620 d](/filings/0001193125-26-064849.md) | [608](/filings/0000950170-25-061313.md) | [598](/filings/0000950170-25-100970.md) | [591](/filings/0001193125-25-266701.md) | [589 d](/filings/0001193125-26-064849.md) | [569](/filings/0001193125-26-192574.md) | [578](/filings/0001193125-26-324169.md) | [613](/filings/0001193125-25-266701.md) | [630 d](/filings/0001193125-26-064849.md) | [608](/filings/0001193125-26-192574.md) | [678](/filings/0001193125-26-324169.md) |
| Gross profit | $m | [69.1](/filings/0000950170-24-119684.md) | [71.0 d](/filings/0001193125-26-064849.md) | [67.4](/filings/0000950170-25-061313.md) | [68.0](/filings/0000950170-25-100970.md) | [66.7](/filings/0001193125-25-266701.md) | [67.9 d](/filings/0001193125-26-064849.md) | [63.2](/filings/0001193125-26-192574.md) | [64.8](/filings/0001193125-26-324169.md) | [67.9](/filings/0001193125-25-266701.md) | [74.2 d](/filings/0001193125-26-064849.md) | [69.2](/filings/0001193125-26-192574.md) | [78.4](/filings/0001193125-26-324169.md) |
| Selling, general and administrative | $m | [35.5](/filings/0000950170-24-119684.md) | [35.6 d](/filings/0001193125-26-064849.md) | [37.3](/filings/0000950170-25-061313.md) | [38.0](/filings/0000950170-25-100970.md) | [36.6](/filings/0001193125-25-266701.md) | [37.5 d](/filings/0001193125-26-064849.md) | [38.8](/filings/0001193125-26-192574.md) | [40.6](/filings/0001193125-26-324169.md) | [41.5](/filings/0001193125-25-266701.md) | [38.8 d](/filings/0001193125-26-064849.md) | [42.4](/filings/0001193125-26-192574.md) | [46.1](/filings/0001193125-26-324169.md) |
| Operating income | $m | [30.3](/filings/0000950170-24-119684.md) | [32.1 d](/filings/0001193125-26-064849.md) | [25.5](/filings/0000950170-25-061313.md) | [27.3](/filings/0000950170-25-100970.md) | [28.1](/filings/0001193125-25-266701.md) | [28.5 d](/filings/0001193125-26-064849.md) | [11.8](/filings/0001193125-26-192574.md) | [20.5](/filings/0001193125-26-324169.md) | [23.7](/filings/0001193125-25-266701.md) | [20.1 d](/filings/0001193125-26-064849.md) | [21.9](/filings/0001193125-26-192574.md) | [30.3](/filings/0001193125-26-324169.md) |
| Interest expense | $m | [8.5](/filings/0000950170-24-119684.md) | [8.7 d](/filings/0001193125-26-064849.md) | [7.2](/filings/0000950170-25-061313.md) | [6.9](/filings/0000950170-25-100970.md) | [6.6](/filings/0001193125-25-266701.md) | [6.2 d](/filings/0001193125-26-064849.md) | [5.3](/filings/0001193125-26-192574.md) | [6.3](/filings/0001193125-26-324169.md) | [4.4](/filings/0001193125-25-266701.md) | [4.1 d](/filings/0001193125-26-064849.md) | [3.6](/filings/0001193125-26-192574.md) | [3.8](/filings/0001193125-26-324169.md) |
| Income tax | $m | [5.2](/filings/0000950170-24-119684.md) | [0.2 d](/filings/0001193125-26-064849.md) | [5.1](/filings/0000950170-25-061313.md) | [5.0](/filings/0000950170-25-100970.md) | [5.0](/filings/0001193125-25-266701.md) | [7.7 d](/filings/0001193125-26-064849.md) | [4.8](/filings/0001193125-26-192574.md) | [15.6](/filings/0001193125-26-324169.md) | [6.3](/filings/0001193125-25-266701.md) | [10.0 d](/filings/0001193125-26-064849.md) | [5.4](/filings/0001193125-26-192574.md) | [8.8](/filings/0001193125-26-324169.md) |
| Net income | $m | [20.4](/filings/0000950170-24-119684.md) | [22.2 d](/filings/0001193125-26-064849.md) | [14.0](/filings/0000950170-25-061313.md) | [15.5](/filings/0000950170-25-100970.md) | [15.4](/filings/0001193125-25-266701.md) | [16.2 d](/filings/0001193125-26-064849.md) | [3.6](/filings/0001193125-26-192574.md) | [1.0](/filings/0001193125-26-324169.md) | [14.3](/filings/0001193125-25-266701.md) | [6.0 d](/filings/0001193125-26-064849.md) | [13.0](/filings/0001193125-26-192574.md) | [19.9](/filings/0001193125-26-324169.md) |
| Diluted EPS | $ per share | [0.57](/filings/0000950170-24-119684.md) | not reported | [0.38](/filings/0000950170-25-061313.md) | [0.43](/filings/0000950170-25-100970.md) | [0.42](/filings/0001193125-25-266701.md) | not reported | [0.10](/filings/0001193125-26-192574.md) | [0.03](/filings/0001193125-26-324169.md) | [0.39](/filings/0001193125-25-266701.md) | not reported | [0.36](/filings/0001193125-26-192574.md) | [0.55](/filings/0001193125-26-324169.md) |
| Basic EPS | $ per share | [0.57](/filings/0000950170-24-119684.md) | not reported | [0.39](/filings/0000950170-25-061313.md) | [0.43](/filings/0000950170-25-100970.md) | [0.43](/filings/0001193125-25-266701.md) | not reported | [0.10](/filings/0001193125-26-192574.md) | [0.03](/filings/0001193125-26-324169.md) | [0.40](/filings/0001193125-25-266701.md) | not reported | [0.36](/filings/0001193125-26-192574.md) | [0.55](/filings/0001193125-26-324169.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q1 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [260](/filings/0000950170-23-057674.md) | [277](/filings/0000950170-25-029247.md) | [296](/filings/0000950170-24-052438.md) | [309](/filings/0000950170-24-088810.md) | [324](/filings/0000950170-24-119684.md) | [315](/filings/0001193125-26-064849.md) | [355](/filings/0000950170-25-061313.md) | [265](/filings/0000950170-25-100970.md) | [285](/filings/0001193125-25-266701.md) | [322](/filings/0001193125-26-324169.md) | [325](/filings/0001193125-26-192574.md) | [315](/filings/0001193125-26-324169.md) |
| Current assets | $m | [1,707](/filings/0000950170-23-057674.md) | [1,636](/filings/0000950170-25-029247.md) | [1,579](/filings/0000950170-24-052438.md) | [1,511](/filings/0000950170-24-088810.md) | [1,509](/filings/0000950170-24-119684.md) | [1,506](/filings/0001193125-26-064849.md) | [1,505](/filings/0000950170-25-061313.md) | [1,397](/filings/0000950170-25-100970.md) | [1,435](/filings/0001193125-25-266701.md) | [1,448](/filings/0001193125-26-324169.md) | [1,460](/filings/0001193125-26-192574.md) | [1,585](/filings/0001193125-26-324169.md) |
| Total assets | $m | [2,333](/filings/0000950170-23-057674.md) | [2,275](/filings/0000950170-25-029247.md) | [2,213](/filings/0000950170-24-052438.md) | [2,155](/filings/0000950170-24-088810.md) | [2,149](/filings/0000950170-24-119684.md) | [2,134](/filings/0001193125-26-064849.md) | [2,136](/filings/0000950170-25-061313.md) | [2,031](/filings/0000950170-25-100970.md) | [2,067](/filings/0001193125-25-266701.md) | [2,072](/filings/0001193125-26-324169.md) | [2,096](/filings/0001193125-26-192574.md) | [2,214](/filings/0001193125-26-324169.md) |
| Current liabilities | $m | [699](/filings/0000950170-23-057674.md) | [714](/filings/0000950170-25-029247.md) | [668](/filings/0000950170-24-052438.md) | [643](/filings/0000950170-24-088810.md) | [639](/filings/0000950170-24-119684.md) | [649](/filings/0001193125-26-064849.md) | [636](/filings/0000950170-25-061313.md) | [592](/filings/0000950170-25-100970.md) | [619](/filings/0001193125-25-266701.md) | [636](/filings/0001193125-26-324169.md) | [669](/filings/0001193125-26-192574.md) | [795](/filings/0001193125-26-324169.md) |
| Total liabilities | $m | not reported | not reported | not reported | not reported | not reported | [1,030](/filings/0001193125-26-064849.md) | [1,031](/filings/0000950170-25-061313.md) | [924](/filings/0000950170-25-100970.md) | [958](/filings/0001193125-25-266701.md) | [972](/filings/0001193125-26-324169.md) | [1,000](/filings/0001193125-26-192574.md) | [1,098](/filings/0001193125-26-324169.md) |
| Long-term debt | $m | [432](/filings/0000950170-23-057674.md) | [331](/filings/0000950170-25-029247.md) | [315](/filings/0000950170-24-052438.md) | [289](/filings/0000950170-24-088810.md) | [279](/filings/0000950170-24-119684.md) | [257](/filings/0001193125-26-064849.md) | [276](/filings/0000950170-25-061313.md) | [207](/filings/0000950170-25-100970.md) | [216](/filings/0001193125-25-266701.md) | [211](/filings/0001193125-26-324169.md) | [205](/filings/0001193125-26-192574.md) | [181](/filings/0001193125-26-324169.md) |
| Shareholders' equity | $m | [1,063](/filings/0000950170-23-057674.md) | [1,079](/filings/0000950170-25-029247.md) | [1,085](/filings/0000950170-24-052438.md) | [1,095](/filings/0000950170-24-088810.md) | [1,103](/filings/0000950170-24-119684.md) | [1,105](/filings/0001193125-26-064849.md) | [1,105](/filings/0000950170-25-061313.md) | [1,107](/filings/0000950170-25-100970.md) | [1,109](/filings/0001193125-25-266701.md) | [1,100](/filings/0001193125-26-324169.md) | [1,097](/filings/0001193125-26-192574.md) | [1,116](/filings/0001193125-26-324169.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [37.6 d](/filings/0000950170-24-119684.md) | [137 d](/filings/0001193125-26-064849.md) | [48.5](/filings/0000950170-25-061313.md) | [55.8 d](/filings/0000950170-25-100970.md) | [39.0 d](/filings/0001193125-25-266701.md) | [45.9 d](/filings/0001193125-26-064849.md) | [31.5](/filings/0001193125-26-192574.md) | [(2.8) d](/filings/0001193125-26-324169.md) | [36.6 d](/filings/0001193125-25-266701.md) | [58.7 d](/filings/0001193125-26-064849.md) | [47.0](/filings/0001193125-26-192574.md) | [34.7 d](/filings/0001193125-26-324169.md) |
| Capital expenditure | $m | [19.7](/filings/0000950170-24-119684.md) | [9.5 d](/filings/0001193125-26-064849.md) | [5.2](/filings/0000950170-25-061313.md) | [8.5](/filings/0000950170-25-100970.md) | [9.8](/filings/0001193125-25-266701.md) | [8.8 d](/filings/0001193125-26-064849.md) | [3.4](/filings/0001193125-26-192574.md) | [12.3](/filings/0001193125-26-324169.md) | [11.5](/filings/0001193125-25-266701.md) | [10.4 d](/filings/0001193125-26-064849.md) | [16.0](/filings/0001193125-26-192574.md) | [12.9](/filings/0001193125-26-324169.md) |
| Dividends paid | $m | [5.9](/filings/0000950170-24-119684.md) | [5.9 d](/filings/0001193125-26-064849.md) | [5.9](/filings/0000950170-25-061313.md) | [5.9](/filings/0000950170-25-100970.md) | [6.0](/filings/0001193125-25-266701.md) | [6.1 d](/filings/0001193125-26-064849.md) | [6.1](/filings/0001193125-26-192574.md) | [6.1](/filings/0001193125-26-324169.md) | [6.1](/filings/0001193125-25-266701.md) | [6.1 d](/filings/0001193125-26-064849.md) | [6.1](/filings/0001193125-26-192574.md) | [6.1](/filings/0001193125-26-324169.md) |
| Share repurchases | $m | [0.0 d](/filings/0000950170-24-119684.md) | [0.0 d](/filings/0001193125-26-064849.md) | [0.0](/filings/0000950170-25-061313.md) | [0.0 d](/filings/0000950170-25-100970.md) | [5.1 d](/filings/0001193125-25-266701.md) | [(0.0) d](/filings/0001193125-26-064849.md) | [8.0](/filings/0001193125-26-192574.md) | [8.0 d](/filings/0001193125-26-324169.md) | [10.0 d](/filings/0001193125-25-266701.md) | [0.9 d](/filings/0001193125-26-064849.md) | [5.8](/filings/0001193125-26-192574.md) | [0.0 d](/filings/0001193125-26-324169.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets, us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q3 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q1 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [35.3](/filings/0000950170-23-057674.md) | [35.6](/filings/0000950170-24-052438.md) | [35.7](/filings/0000950170-24-088810.md) | [35.9](/filings/0000950170-24-119684.md) | [36.4](/filings/0000950170-25-061313.md) | [36.5](/filings/0000950170-25-100970.md) | [36.6](/filings/0001193125-25-266701.md) | [36.6](/filings/0001193125-26-192574.md) | [36.3](/filings/0001193125-26-324169.md) | [36.2](/filings/0001193125-25-266701.md) | [36.3](/filings/0001193125-26-192574.md) | [36.4](/filings/0001193125-26-324169.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 35,919,933 at 2026-07-27, from the cover of the [10-Q filed 2026-07-29](/filings/0001193125-26-324169.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:26 ET. No prices; not investment advice.